MX2023001689A - Inhibidores de bcl-2. - Google Patents
Inhibidores de bcl-2.Info
- Publication number
- MX2023001689A MX2023001689A MX2023001689A MX2023001689A MX2023001689A MX 2023001689 A MX2023001689 A MX 2023001689A MX 2023001689 A MX2023001689 A MX 2023001689A MX 2023001689 A MX2023001689 A MX 2023001689A MX 2023001689 A MX2023001689 A MX 2023001689A
- Authority
- MX
- Mexico
- Prior art keywords
- bcl
- treating
- inhibitors
- disclosed
- undesirable
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 abstract 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describe en este documento un compuesto de fórmula (I) para inhibir Bcl-2 y tratar enfermedades asociadas con actividad indeseable de bcl-2 (enfermedades relacionadas con Bcl-2), un método para usar los compuestos descritos en este documento para tratar enfermedades apoptóticas desreguladas, incluidos cánceres, y tratamiento de enfermedad autoinmune, y una composición farmacéutica que la comprende.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018085217 | 2018-04-29 | ||
CN2018107134 | 2018-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023001689A true MX2023001689A (es) | 2023-02-22 |
Family
ID=68386968
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011495A MX2020011495A (es) | 2018-04-29 | 2019-04-29 | Inhibidores de bcl-2. |
MX2023001689A MX2023001689A (es) | 2018-04-29 | 2020-10-29 | Inhibidores de bcl-2. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020011495A MX2020011495A (es) | 2018-04-29 | 2019-04-29 | Inhibidores de bcl-2. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11420968B2 (es) |
EP (1) | EP3788042A4 (es) |
JP (1) | JP2021521138A (es) |
KR (1) | KR20210005677A (es) |
CN (3) | CN112437772B (es) |
AU (1) | AU2019264475A1 (es) |
BR (1) | BR112020022092A2 (es) |
CA (1) | CA3098348A1 (es) |
MX (2) | MX2020011495A (es) |
SG (1) | SG11202009933WA (es) |
TW (1) | TW202043217A (es) |
WO (1) | WO2019210828A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3565815B1 (en) | 2017-01-07 | 2024-03-13 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
JP7085566B2 (ja) | 2017-04-18 | 2022-06-16 | シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド | アポトーシス誘発剤 |
JP2021510163A (ja) | 2018-01-10 | 2021-04-15 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | ベンズアミド化合物 |
BR112020022092A2 (pt) | 2018-04-29 | 2021-02-02 | Beigene, Ltd. | compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica |
US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
US20230002369A1 (en) * | 2019-10-28 | 2023-01-05 | Beigene, Ltd. | Bcl-2 INHIBITORS |
WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
US20230041515A1 (en) | 2019-12-06 | 2023-02-09 | Loxo Oncology, Inc. | Dosing of a bruton's tyrosine kinase inhibitor |
WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
EP4136084A4 (en) * | 2020-04-15 | 2023-11-01 | BeiGene, Ltd. | BCL-2 INHIBITOR |
US20230159527A1 (en) * | 2020-05-08 | 2023-05-25 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
WO2022089463A1 (zh) * | 2020-10-28 | 2022-05-05 | 杭州和正医药有限公司 | Bcl-2蛋白凋亡诱导剂及应用 |
CN117642157A (zh) * | 2021-03-19 | 2024-03-01 | 伊尔治疗学股份有限公司 | 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物 |
CN117616023A (zh) * | 2021-04-13 | 2024-02-27 | 爱新医药科技(香港)有限公司 | Bcl-2或bcl-2/bcl-xl调节剂及其用途 |
IL308931A (en) * | 2021-06-02 | 2024-01-01 | Beigene Switzerland Gmbh | Methods for treating malignant B cells using a Bcl-2 inhibitor |
CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
IL311106A (en) * | 2021-08-31 | 2024-04-01 | Beigene Ltd | Solid forms of BCL-2 inhibitors, their method of preparation and use |
WO2023078398A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
AU2022394660A1 (en) * | 2021-11-20 | 2024-06-06 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
CA3238433A1 (en) * | 2021-12-06 | 2023-06-15 | Xingguo LIU | Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof |
TW202400163A (zh) | 2022-05-12 | 2024-01-01 | 英屬開曼群島商百濟神州有限公司 | 使用bcl-2抑制劑治療髓性惡性腫瘤之方法 |
WO2023231777A1 (en) * | 2022-06-01 | 2023-12-07 | Fochon Pharmaceuticals, Ltd. | Compounds as bcl-2 inhibitors |
WO2024017354A1 (en) * | 2022-07-21 | 2024-01-25 | Beigene, Ltd. | Methods of treating multiple myeloma using bcl-2 inhibitor |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US20020055631A1 (en) * | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
WO2006023778A2 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
AU2006297853B2 (en) | 2005-05-12 | 2010-08-19 | AbbVie Global Enterprises Ltd. | Apoptosis promoters |
US7777076B2 (en) | 2005-05-24 | 2010-08-17 | Abbott Laboratories | Macrocyclic inhibitors of BCL proteins |
EP2061560A2 (en) | 2006-09-05 | 2009-05-27 | Abbott Laboratories | Bcl inhibitors for treating platelet excess |
WO2009036051A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors containing a zinc binding moiety |
CN102112445B (zh) | 2008-06-09 | 2014-06-18 | 百时美施贵宝公司 | 作为抗细胞凋亡Bcl抑制剂的羟基苯基磺酰胺 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
UA108193C2 (uk) | 2008-12-04 | 2015-04-10 | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
EP3666758A1 (en) | 2008-12-05 | 2020-06-17 | AbbVie Inc. | Process for the preparation of a sulfonamide derivative |
JP5736318B2 (ja) | 2008-12-08 | 2015-06-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するための化合物 |
AU2010204555B2 (en) | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
NZ616828A (en) | 2009-01-19 | 2015-03-27 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
DK2435432T6 (da) | 2009-05-26 | 2023-12-18 | Abbvie Ireland Unlimited Co | Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
AU2010294292B2 (en) | 2009-09-10 | 2013-07-18 | Novartis Ag | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatment of cancer |
RU2568611C2 (ru) | 2010-03-25 | 2015-11-20 | Эббви Инк. | Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний |
TWI520960B (zh) | 2010-05-26 | 2016-02-11 | 艾伯維有限公司 | 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑 |
TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
CA2811805A1 (en) | 2010-10-29 | 2012-05-03 | Abbvie Inc. | Solid dispersions containing an apoptosis-inducing agent |
IT1403156B1 (it) | 2010-12-01 | 2013-10-04 | Università Degli Studi Di Torino | Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi. |
JP5998152B2 (ja) | 2011-01-25 | 2016-09-28 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Bcl−2/bcl−xl阻害剤およびそれを使用する治療方法 |
CN103732589B (zh) | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
CN104039797B (zh) | 2011-10-12 | 2016-06-01 | 南京奥昭生物科技有限公司 | 作为细胞凋亡诱导剂的杂环分子 |
EA201491259A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания |
KR20140107575A (ko) | 2011-12-23 | 2014-09-04 | 노파르티스 아게 | Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물 |
AU2012355624A1 (en) | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
CA2859862A1 (en) | 2011-12-23 | 2013-06-27 | Novartis Ag | Compounds for inhibiting the interaction of bcl2 with binding partners |
EA201491264A1 (ru) | 2011-12-23 | 2014-11-28 | Новартис Аг | Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию |
WO2013185202A1 (en) | 2012-06-14 | 2013-12-19 | Beta Pharma Canada Inc | Apoptosis inducers |
CA2897055C (en) | 2013-01-16 | 2021-04-20 | The Regents Of The University Of Michigan | Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
EP3481397A1 (en) | 2016-07-06 | 2019-05-15 | Concert Pharmaceuticals Inc. | Deuterated venetoclax |
EP3569601B1 (en) | 2016-08-05 | 2022-06-22 | The Regents of The University of Michigan | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors |
WO2018041248A1 (zh) | 2016-09-01 | 2018-03-08 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
CN106565706B (zh) | 2016-10-27 | 2018-05-01 | 广东东阳光药业有限公司 | 一种磺酰胺衍生物及其在药学中的应用 |
CN106749233B (zh) * | 2016-11-24 | 2020-04-21 | 中山大学 | 一类磺酰胺衍生物及其应用 |
BR112020022092A2 (pt) | 2018-04-29 | 2021-02-02 | Beigene, Ltd. | compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica |
US20220073513A1 (en) | 2018-12-29 | 2022-03-10 | Newave Pharmaceutical Inc. | 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
-
2019
- 2019-04-29 BR BR112020022092-2A patent/BR112020022092A2/pt unknown
- 2019-04-29 AU AU2019264475A patent/AU2019264475A1/en active Pending
- 2019-04-29 CN CN201980029015.1A patent/CN112437772B/zh active Active
- 2019-04-29 MX MX2020011495A patent/MX2020011495A/es unknown
- 2019-04-29 KR KR1020207033817A patent/KR20210005677A/ko not_active Application Discontinuation
- 2019-04-29 CN CN202311185016.XA patent/CN117430601A/zh active Pending
- 2019-04-29 CN CN202311486964.7A patent/CN117683029A/zh active Pending
- 2019-04-29 SG SG11202009933WA patent/SG11202009933WA/en unknown
- 2019-04-29 WO PCT/CN2019/085001 patent/WO2019210828A1/en unknown
- 2019-04-29 US US17/050,581 patent/US11420968B2/en active Active
- 2019-04-29 EP EP19797052.8A patent/EP3788042A4/en active Pending
- 2019-04-29 CA CA3098348A patent/CA3098348A1/en active Pending
- 2019-04-29 JP JP2020555218A patent/JP2021521138A/ja active Pending
-
2020
- 2020-04-28 TW TW109114185A patent/TW202043217A/zh unknown
- 2020-10-29 MX MX2023001689A patent/MX2023001689A/es unknown
-
2022
- 2022-05-23 US US17/750,821 patent/US20220402915A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3788042A4 (en) | 2022-01-26 |
SG11202009933WA (en) | 2020-11-27 |
MX2020011495A (es) | 2021-01-15 |
CA3098348A1 (en) | 2019-11-07 |
EP3788042A1 (en) | 2021-03-10 |
CN112437772B (zh) | 2023-11-21 |
US11420968B2 (en) | 2022-08-23 |
JP2021521138A (ja) | 2021-08-26 |
CN117683029A (zh) | 2024-03-12 |
CN112437772A (zh) | 2021-03-02 |
WO2019210828A1 (en) | 2019-11-07 |
CN117430601A (zh) | 2024-01-23 |
AU2019264475A1 (en) | 2020-11-12 |
BR112020022092A2 (pt) | 2021-02-02 |
TW202043217A (zh) | 2020-12-01 |
US20210269433A1 (en) | 2021-09-02 |
KR20210005677A (ko) | 2021-01-14 |
US20220402915A1 (en) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001689A (es) | Inhibidores de bcl-2. | |
CR20220363A (es) | Compuestos tricíclicos sustituidos | |
CR20220312A (es) | Compuestos tricíclicos sustituidos | |
JOP20190186A1 (ar) | مركب كينازولين | |
EP4269440A3 (en) | Composition for treating il-6-related diseases | |
MX2023005636A (es) | Inhibidores de bcl6 derivados de bencimidazolona. | |
PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
MX2023002507A (es) | Inhibidores de cd73. | |
MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
MX2019005934A (es) | Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac). | |
NZ788133A (en) | Cd73 inhibitors | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
MX2021007247A (es) | Derivados de rapamicina. | |
ZA202300912B (en) | Tyk-2 inhibitor | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2021012105A (es) | Compuestos de pirrol. | |
PH12021550304A1 (en) | Novel medicament for treating inflammatory bowel disease | |
SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
MX2022002446A (es) | Compuestos de pirrolopirimidina inhibidores de perk. | |
ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
MX2022002443A (es) | Compuestos inhibidores de perk. | |
MX2021014458A (es) | Compuestos triciclicos. |